Physiological Study to Compare Noninvasive Ventilation (NIV) Masks

Hypercapnia Clinical Trial

Official title:

Physiological Study to Compare Noninvasive Ventilation (NIV) Masks

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04926805
• Other study ID #: CIA-279
• Secondary ID: U1111-1259-4797
• Status: Terminated
• Phase: N/A
• Start date: July 7, 2021
• Est. completion date: July 5, 2023

Study information

• Verified date: July 2023
• Source: Fisher and Paykel Healthcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Noninvasive ventilation (NIV) is an established therapy that delivers positive pressure to the upper airways to provide respiratory support. Two types of NIV can be delivered; continuous positive airway pressure (CPAP) at one continuous pressure and bilevel NIV at two pressures for inhalation and exhalation. This investigation is designed to physiologically evaluate the performance of a NIV mask, Mask A, compared to a standard NIV mask, Mask B on CPAP therapy. People with sleep disordered breathing who have chronic hypercapnia, and are already receiving nocturnal CPAP will be recruited. They will receive one night's CPAP therapy on Mask A and 1 night on Mask B in random order. Physiological parameters will be recorded. Parameters will be recorded during three baselines at the beginning of each evening and throughout the night when participants are asleep. The three baselines are: 1. participant awake with normal breathing (not on CPAP), 2. participant awake and on CPAP, and 3. participant asleep on CPAP in REM-sleep (rapid eye movement sleep).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: July 5, 2023
• Est. primary completion date: October 14, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Already using overnight CPAP and tolerating the therapy well (over 4 hours use/night)
• Hypercapnia: venous bicarbonate of 30 milliequivalents of solute per liter (Eq/L) or more, OR transcutaneous carbon dioxide (TcCO2) of 50 millimeters of mercury (mmHg) of more.
• Provide written informed consent
• Already use a full (oronasal) face mask for CPAP
• Willing to have a venous blood sample taken during the pre-screening visit.

Exclusion Criteria:

• Presence of sleep apnea on CPAP:
• Subjects excluded if they have an apnea-hypopnea index (AHI) of more than 20, or
• If the AHI has not already decreased by 50 percent or more from pre-CPAP to with CPAP.
• Forced expiratory volume in 1 second (FEV1) of less than 40 percent of predicted.
• Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC) less than fifty percent of predicted, at the screening visit.
• Have poorly controlled asthma or changing asthma symptoms.
• Nasal obstruction
• Do not fit Mask A or Mask B
• Agitation or psychological illness

Related Conditions & MeSH terms

• Hypercapnia
• Sleep Apnea Syndromes
• Sleep-disordered Breathing

Intervention

Device:
• CPAP with Mask A
CPAP mask
• CPAP with Mask B
CPAP mask

Locations

Country	Name	City	State
New Zealand	New Zealand Respiratory and Sleep Institute	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Fisher and Paykel Healthcare

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Transcutaneous carbon dioxide	The change in transcutaneous carbon dioxide from the 3 different baselines to the transcutaneous carbon dioxide during non-REM sleep on CPAP on the same study night. Three different values will be determined for each mask.	1 day (From baseline to the end of the study night)